肝素类制品研究概述
|
摘要
肝素在临床上主要用于血液透析、血栓栓塞性疾病、心血管手术、心脏导管检查等,是防治血栓形成、肺栓塞、弥漫性血管内凝血的首选药物,具有抗凝效果好、副作用小、安全性高等优势。本文通过对肝素类制品类别及制备方法进展,对肝素类制备的发展趋势进行探讨。
Heparin is mainly used in the clinic for hemodialysis, thromboembolic diseases, cardiovascular surgery, cardiac catheterization, etc. It is the first choice for the prevention and treatment of thrombosis, pulmonary embolism, and disseminated intravascular coagulation.In this paper, the classification of heparin products and the preparation methods were reviewed, and the development trend of heparin preparation was discussed.
Heparin is mainly used in the clinic for hemodialysis, thromboembolic diseases, cardiovascular surgery, cardiac catheterization, etc. It is the first choice for the prevention and treatment of thrombosis, pulmonary embolism, and disseminated intravascular coagulation.In this paper, the classification of heparin products and the preparation methods were reviewed, and the development trend of heparin preparation was discussed.
引文
[1]Linhardt RJ,Claude S.HudsonAward Address in Carbohydrate Chemistry.Heparin:Structure and activity[J].JMedChem,2003,46(13):2551-2564.
[2]Elaine Gray, Barbara Mulloy, Trevor W. Barrowcliffe. Heparin and lowmolecular-weight heparin[J]. ThrombHaemost,2008,99(5):807-818.
[3]石欣.一种利用猪小肠提取肝素钠粗品的方法:中国,200910018967[P].2009-09-22.
[4]臧盛,于福满,程榆茗,等.利用猪肺提取肝素钠粗品的制备工艺:中国,201110161138[P].2011-06-15.
[3]马志科,马丽.动物器官中肝素钠提取方法研究进展[J].动物医学进展,2016,37(5):106-108.
[4]海文英,万端极,吴正奇,等.酶法结合膜技术制备高效价肝素钠的工艺研究[J].科学技术与工程,2013,13(11):3069-3072.
[5]张天民,王凤山.低分子肝素研究进展[J].中国生化药物杂志,1998,19(4):194-195.
[6]张丽萍,李雷刚,马中苏.亚硝酸降解法制备低分子肝素的工艺参数优化与确定[J].药物分析杂志,2009(7):1148-1152.
[7]FDA. LOVENOX(Enoxaparin Sodium)injection[EB/OL]. US:Foodand Drug Administration,2017[2018-1106].https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020164s110lbl.pdf.
[8] FDA. Innohep?(tinzaparin sodium injection)[EB/OL].US:Foodand Drug Administration, 2010[2018-1106]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020484s014lbl.pdf.
[9]邢新会,叶逢春,张翀.一种制备超低分子量肝素的方法:中国,200910092339[P].2009-09-10.
[10]王秀云,姬胜利,肖佳普.一种超低分子量肝素的制备及纯化工艺:中国,200910180282[P].2009-10-13.
[11]李晓燕.生物酶法合成肝素的多种关键酶制备和酶反应工程研究[D].杭州:浙江大学,2016.
[12]FDA. ARIXTRA(fondaparinux sodium injection)[EB/OL]. US:Foodand Drug Administration, 2017[2018-1106]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021345s035lbl. pdf.
[13]BKuberan, David L. Beeler, MiroslawLech,et al. Chemoenzymatic Synthesis of Classical and Non-classical Anticoagulant Heparan Sulfate Polysaccharides[J]. The Journal of Biological Chemistry,2003,278(52):52613–52621.
[14]Xu YM,Masuko S, Takieddin M,et al.Chemoenzymatic Synthesis ofHomogeneousUltralowMolecularWeightHeparins[J].Science,2011,334:498-501.
[15]Wang Z, Hsieh P H, Xu Y, et al. Synthesis of 3-O-sulfated oligosaccharides to understand the relationship between structures and functions of heparansulfate[J]. Journal of the American Chemical Society, 2017:jacs.7b01923.
[16]BlossomDB,KallenAJ,PatelPR.OutbreakofAdverse Reactions Associated WithContaminatedHeparin[J].N Engl J Med,2008,359(25):2674-2684.
[2]Elaine Gray, Barbara Mulloy, Trevor W. Barrowcliffe. Heparin and lowmolecular-weight heparin[J]. ThrombHaemost,2008,99(5):807-818.
[3]石欣.一种利用猪小肠提取肝素钠粗品的方法:中国,200910018967[P].2009-09-22.
[4]臧盛,于福满,程榆茗,等.利用猪肺提取肝素钠粗品的制备工艺:中国,201110161138[P].2011-06-15.
[3]马志科,马丽.动物器官中肝素钠提取方法研究进展[J].动物医学进展,2016,37(5):106-108.
[4]海文英,万端极,吴正奇,等.酶法结合膜技术制备高效价肝素钠的工艺研究[J].科学技术与工程,2013,13(11):3069-3072.
[5]张天民,王凤山.低分子肝素研究进展[J].中国生化药物杂志,1998,19(4):194-195.
[6]张丽萍,李雷刚,马中苏.亚硝酸降解法制备低分子肝素的工艺参数优化与确定[J].药物分析杂志,2009(7):1148-1152.
[7]FDA. LOVENOX(Enoxaparin Sodium)injection[EB/OL]. US:Foodand Drug Administration,2017[2018-1106].https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020164s110lbl.pdf.
[8] FDA. Innohep?(tinzaparin sodium injection)[EB/OL].US:Foodand Drug Administration, 2010[2018-1106]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020484s014lbl.pdf.
[9]邢新会,叶逢春,张翀.一种制备超低分子量肝素的方法:中国,200910092339[P].2009-09-10.
[10]王秀云,姬胜利,肖佳普.一种超低分子量肝素的制备及纯化工艺:中国,200910180282[P].2009-10-13.
[11]李晓燕.生物酶法合成肝素的多种关键酶制备和酶反应工程研究[D].杭州:浙江大学,2016.
[12]FDA. ARIXTRA(fondaparinux sodium injection)[EB/OL]. US:Foodand Drug Administration, 2017[2018-1106]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021345s035lbl. pdf.
[13]BKuberan, David L. Beeler, MiroslawLech,et al. Chemoenzymatic Synthesis of Classical and Non-classical Anticoagulant Heparan Sulfate Polysaccharides[J]. The Journal of Biological Chemistry,2003,278(52):52613–52621.
[14]Xu YM,Masuko S, Takieddin M,et al.Chemoenzymatic Synthesis ofHomogeneousUltralowMolecularWeightHeparins[J].Science,2011,334:498-501.
[15]Wang Z, Hsieh P H, Xu Y, et al. Synthesis of 3-O-sulfated oligosaccharides to understand the relationship between structures and functions of heparansulfate[J]. Journal of the American Chemical Society, 2017:jacs.7b01923.
[16]BlossomDB,KallenAJ,PatelPR.OutbreakofAdverse Reactions Associated WithContaminatedHeparin[J].N Engl J Med,2008,359(25):2674-2684.